MarTech Vendor · vs · Data Provider / Broker
Oracle vs Veeva
Structured technology and market comparison · 2026
Direct Feature Comparison
Oracle · vs · VeevaEnterprise cloud infrastructure and customer experience software provider.
Life sciences cloud software and data platform provider.
Analyze all overlapping signals and tech stacks for Oracle and Veeva
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Oracle and Veeva?
Oracle provides broad horizontal cloud infrastructure and diverse enterprise applications across all industries, focusing on deep ecosystem integration from database to CX layers. In contrast, Veeva is a vertical specialist dedicated to the life sciences sector, emphasizing regulatory compliance and industry-specific workflows. While Oracle prioritizes massive scale and architectural breadth, Veeva differentiates through purpose-built solutions for pharmaceutical and biotech product lifecycles.
How do the features of Oracle and Veeva compare?
Oracles product suite encompasses extensive cloud infrastructure, database management, and horizontal CX modules suitable for diverse corporate functions. Veeva offers a verticalized platform featuring clinical, regulatory, and quality control tools specifically for life sciences. While both provide CRM and data management capabilities, Veeva includes specialized compliance features for regulated environments that Oracle lacks, whereas Oracle provides superior underlying infrastructure and hardware integration.
What are the top alternatives to Oracle and Veeva?
When evaluating Oracle and Veeva, enterprise buyers also consider other platforms in Customer Relationship Management (CRM), Cloud Data Warehouse / Data Lake, and Customer Data & Clean Room Platform (CDP/DCR). You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Oracle and Veeva compare?
Oracle is headquartered in United States (founded in 1977) with >5,000 employees. Veeva is based in United States (founded in 2007) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Oracle vs Veeva
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Oracle
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Oracle (2026-10-28)
On October 28, 2026, Oracle Corporation filed a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) regarding materials furnished in connection with its 2026 Investor Day. The filing announces the issuance of a press release detailing Oracle's updated corporate strategy and forward-looking financial guidance. Although the specific operational targets and numerical projections were furnished via Exhibit 99.1 rather than within the core filing body, the filing formally documents Oracle's strategic communication to institutional markets and financial analysts regarding its long-term financial trajectory.
- Oracle issued a press release on October 28, 2026, outlining corporate strategy and financial guidance in conjunction with its 2026 Investor Day.
- The disclosure was submitted under Item 7.01 (Regulation FD) and incorporates Exhibit 99.1 (Investor Day Press Release).
- The filing was formally authorized and signed by Kimberly Woolley, Senior Vice President, Assistant General Counsel and Assistant Secretary.
- ·CNBC TechnologyFinancials
Oracle stock surges on 35% revenue growth forecast
Oracle's stock rose sharply after the company issued a long-term revenue forecast of $225 billion for fiscal 2030, implying an average annual growth rate of 35%. Analysts polled by LSEG had expected 8% growth in fiscal 2027, followed by significant acceleration. The company also committed to limiting additional funding for fiscal 2027 through 2030 to $20 billion, split evenly between equity and debt. Oracle stated that vendor financing, customer-provided hardware, and customer prepayments would reduce upfront cash requirements during the transition to positive free cash flow. The announcement eased investor concerns about debt and financing, driving the stock up approximately 11%. This news is relevant for the technology and cloud infrastructure sector, providing a positive outlook for Oracle's growth trajectory.
- Oracle forecasted fiscal 2030 revenue of $225 billion, implying 35% average annual growth.
- Oracle shares surged approximately 11% following the announcement.
- Oracle committed to limit additional funding for fiscal 2027-2030 to $20 billion, split equally between equity and debt.
- ·CNBC InvestingFinancials
AI Debt Fears Ease Ahead of Hyperscaler Earnings
Credit markets are showing signs of easing AI-related debt fears, with credit-default swap (CDS) spreads tightening after a period of volatility, following Meta's announcement of a $95 billion stock offering. However, attention now turns to upcoming earnings and updates from Alphabet, Amazon, Oracle, and Microsoft. Analysts expect both Alphabet and Amazon to report negative free cash flow for the third quarter, with significant capital expenditures. Oracle, with a BBB- rating, is seen as a critical credit risk. Additionally, off-balance sheet arrangements for data centers and chip financing are said to obscure the true extent of AI debt, according to S&P Global Ratings.
- Meta Platforms announced a $95 billion stock offering on Monday, which helped tighten credit-default swap spreads.
- Alphabet and Amazon are expected to report negative free cash flow for Q3, with Alphabet at -$2.3 billion and Amazon at -$9.9 billion.
- Oracle holds an Investor Day on Wednesday and has $117 billion in long-term debt, with a BBB- credit rating.
Veeva
Recent Signals
- ·PR Newswire: Advertising & MarketingLeadership
Omnicom Appoints Tom Schwenger CEO of Health Marketing
Omnicom (NYSE: OMC) has appointed Tom Schwenger as Chief Executive Officer of Omnicom Health's marketing business, effective immediately. Schwenger, who brings over 35 years of experience in pharma, biotech, and healthcare, will oversee the group's global marketing agencies. He succeeds Dana Maiman, who is leaving the company. Schwenger will work with Michael Larson, who remains Chairman of Omnicom Health and will also oversee the specialty health business. The appointment aims to drive accelerated growth, innovation, and AI adoption for clients amid rapid healthcare market evolution. Schwenger joins from Veeva Systems, where he served as President and Chief Customer Officer and tripled revenue. Previously, he spent nearly three decades at Accenture, leading its life sciences practice.
- Omnicom appointed Tom Schwenger as CEO of Omnicom Health's marketing business.
- Tom Schwenger previously served as President and Chief Customer Officer at Veeva Systems.
- Dana Maiman is leaving Omnicom Health after leading the unit.
- ·PR Newswire: Advertising & MarketingAI in Life Sciences Marketing
Veeva Summit to Showcase Agentic AI and Data Innovations
Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other biopharma companies will present new strategies for commercial and medical excellence at the Veeva Commercial Summit, Europe, scheduled for November 18-19, 2026, in Copenhagen. The summit will showcase how industry-specific AI enables sales, marketing, and medical teams to improve customer engagement, derive insights, and accelerate compliant content delivery. Key topics include agentic customer engagement, agentic CRM, agentic MLR for content approvals, and building a data foundation for AI with HCP access data and trusted data platforms. The event will feature over 100 sessions and 1,200+ industry experts, highlighting innovations with Veeva's Commercial Cloud and Data Cloud.
- Veeva Commercial Summit Europe is scheduled for November 18-19, 2026, in Copenhagen.
- The summit will feature over 100 sessions and 1,200+ industry experts.
- AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will present case studies.
- ·PR Newswire: Technology NewsPartnership
IQVIA Expands Veeva Partnership with Clinical Operations Applications
IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.
- IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
- Partnership expansion extends the previously announced EDC partnership.
- All Veeva clinical solutions will be available through IQVIA for sponsors.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Oracle and Veeva share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks